Cost-effectiveness analysis of grass pollen specific immunotherapy in children with allergic rhinitis compared to the standard of care symptomatic treatment in Portugal.

IF 2.6 Q2 ALLERGY European annals of allergy and clinical immunology Pub Date : 2023-09-01 Epub Date: 2021-12-17 DOI:10.23822/EurAnnACI.1764-1489.240

M Farraia, I Paciência, F Castro Mendes, J Cavaleiro Rufo, L Delgado, A Moreira

{"title":"Cost-effectiveness analysis of grass pollen specific immunotherapy in children with allergic rhinitis compared to the standard of care symptomatic treatment in Portugal.","authors":"M Farraia, I Paciência, F Castro Mendes, J Cavaleiro Rufo, L Delgado, A Moreira","doi":"10.23822/EurAnnACI.1764-1489.240","DOIUrl":null,"url":null,"abstract":"Summary: Background. Cost-effectiveness studies evaluating allergen immunotherapy (AIT) in children are scarce. We aim to compare the cost-effectiveness of subcutaneous (SCIT) and sublingual immunotherapy (SLIT) against standard-of-care (SOC) treatment in children with grass pollen allergic rhinitis. Methods. We created a Markov model to compare the three strategies over a 10-year horizon. SOC was the reference to calculate the incremental cost-effectiveness ratio (ICER). Deterministic and probabilistic sensitivity analysis were used to assess models' uncertainty. Results. We obtained an ICER of € 12,605 and € 6,318 for SLIT and SCIT, respectively. In sensitivity analysis, SCIT was more cost-effective than SLIT. Conclusions. AIT is cost-effective in children with grass pollen allergic rhinitis, especially for the subcutaneous route.","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European annals of allergy and clinical immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23822/EurAnnACI.1764-1489.240","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/12/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Summary: Background. Cost-effectiveness studies evaluating allergen immunotherapy (AIT) in children are scarce. We aim to compare the cost-effectiveness of subcutaneous (SCIT) and sublingual immunotherapy (SLIT) against standard-of-care (SOC) treatment in children with grass pollen allergic rhinitis. Methods. We created a Markov model to compare the three strategies over a 10-year horizon. SOC was the reference to calculate the incremental cost-effectiveness ratio (ICER). Deterministic and probabilistic sensitivity analysis were used to assess models' uncertainty. Results. We obtained an ICER of € 12,605 and € 6,318 for SLIT and SCIT, respectively. In sensitivity analysis, SCIT was more cost-effective than SLIT. Conclusions. AIT is cost-effective in children with grass pollen allergic rhinitis, especially for the subcutaneous route.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

草花粉特异性免疫疗法治疗儿童过敏性鼻炎的成本效益分析与葡萄牙标准护理症状治疗的比较。

摘要：背景。评估儿童过敏原免疫疗法（AIT）的成本效益研究很少。我们的目的是比较皮下（SCIT）和舌下免疫疗法（SLIT）与标准护理（SOC）治疗儿童草花粉过敏性鼻炎的成本效益。方法。我们创建了一个马尔可夫模型来比较10年内的三种策略。SOC是计算增量成本效益比（ICER）的参考。确定性和概率敏感性分析用于评估模型的不确定性。后果SLIT和SCIT的ICER分别为12605欧元和6318欧元。在敏感性分析中，SCIT比SLIT更具成本效益。结论。AIT对患有草花粉过敏性鼻炎的儿童具有成本效益，尤其是皮下途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊